Tarveda Therapeutics
Tarveda’s lead Pentarin drug candidate, PEN-221, is a miniaturized drug conjugate that targets the somatostatin receptor 2 (SSTR2) for treatment of patients with neuroendocrine and small cell lung cancers.
Espero BioPharma
ESPERO supports the life science industry to accelerate the delivery of therapies to patients by tackling inefficiencies in protocol creation and implementation.